journal
Journals Expert Review of Clinical Immu...

Expert Review of Clinical Immunology

https://read.qxmd.com/read/37243575/topical-roflumilast-for-the-treatment-of-psoriasis
#1
REVIEW
Anastasia Drakos, Ron Vender, Tiago Torres
INTRODUCTION: New non-steroidal topical agents are needed for the treatment of psoriasis. Roflumilast cream 0.3% is a once daily phosphodiesterase-4 inhibitor that was recently approved by the FDA for the treatment of plaque psoriasis in adolescents and adults. It is indicated for use on all body surfaces including intertriginous areas. AREAS COVERED: In this review, we summarize the current knowledge about roflumilast cream for the treatment of psoriasis, highlighting its efficacy and safety profile from published clinical trials...
May 27, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37226507/evaluation-of-switching-or-simultaneous-use-of-biologic-treatment-in-patients-with-severe-chronic-rhinosinusitis-with-nasal-polyps-and-severe-asthma-considerations-in-clinical-decision-making
#2
JOURNAL ARTICLE
Josje Otten, Rik van der Lans, Eugenio de Corso, Kanstantsin Dziadziulia, Bart Hilvering, Els Weersink, Matteo Bonini, Jan Hagemann, Wanrawee Thaitrakool, Claudio Montuori, Ludger Klimek, Sietze Reitsma, Wytske Fokkens
INTRODUCTION: Type 2 targeting biologics have reached the market first for asthma and since 2019 also for CRSwNP. As clear guidelines and predictors for optimal biological choice are missing, patients are sometimes required to switch biologic therapy in order to find the optimal treatment result. In this paper, we evaluate reasons for switching biologics and the treatment effects after each sequential switch. MATERIALS AND METHODS: 94 patients who switched from one biologic to another for their treatment of CRSwNP and asthma were evaluated...
May 25, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37226522/the-evolving-role-of-jak-inhibitors-in-the-treatment-of-inflammatory-bowel-disease
#3
REVIEW
Nancy Gupta, Sam Papasotiriou, Stephen Hanauer
INTRODUCTION: Janus Kinase inhibitors (JAKi) are a new class of oral therapies for the treatment of moderate-severe ulcerative colitis with additional potential for the treatment of moderate-severe Crohn's disease. In contrast to biologic therapies JAKi provide the opportunity for non-immunogenic once or twice daily oral therapies. AREAS COVERED: Janus Kinase inhibitors for the treatment of ulcerative colitis and Crohn's disease based on mechanism of action, pharmacokinetics, clinical trial and real-world data regarding safety and efficacy; focusing on regulatory approvals in the U...
May 24, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37225659/prognostic-factors-for-post-operative-outcomes-in-chronic-rhinosinusitis-with-nasal-polyps-a-systematic-review
#4
REVIEW
Shiru Cai, Hongfei Lou, Luo Zhang
INTRODUCTION: Chronic rhinosinusitis with nasal polyps (CRSwNP) has a high recurrence rate after surgery despite the availability of medical treatments. Multiple clinical and biological factors have been associated with poor post-operative outcomes in patients with CRSwNP. However, these factors and their prognostic values have not yet been extensively summarized. AREAS COVERED: This systematic review included 49 cohort studies exploring the prognostic factors for post-operative outcomes in CRSwNP...
May 24, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37224535/classification-and-management-strategies-for-paediatric-chronic-nonbacterial-osteomyelitis-and-chronic-recurrent-multifocal-osteomyelitis
#5
REVIEW
Shabnam Singhal, Caren Landes, Rajeev Shukla, Liza J McCann, Christian M Hedrich
INTRODUCTION: Chronic non-bacterial osteomyelitis (CNO) is an autoinflammatory bone disease that most commonly affects children and adolescents causing significant pain and damage to bones. The absence of diagnostic criteria and biomarkers, an incomplete understanding of the molecular pathophysiology, and lack of evidence from randomised and controlled trials make the diagnosis and care challenging. AREAS COVERED: This review provides an overview of clinical and epidemiological features of CNO and displays diagnostic challenges and how they can be addressed following strategies used internationally and by the authors...
May 24, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37199057/updates-in-treatment-and-impact-of-nail-psoriasis
#6
REVIEW
Matilde Iorizzo, Antonella Tosti
INTRODUCTION: Nail psoriasis is an inflammatory disorder without a potential scarring outcome, but the nail signs, even the milder ones, can cause discomfort to patients and severely affect their quality of life. Nail psoriasis may be associated with psoriatic arthritis and when it starts during infancy, it may be a predictor of a more severe disease course in adulthood. All these issues contribute to the high economic burden of psoriasis. AREAS COVERED: Nail psoriasis is notoriously difficult to treat, even though new treatments are in continuous development...
May 17, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37194702/what-place-will-tezepelumab-hold-in-the-treatment-paradigm-in-chronic-rhinosinusitis
#7
EDITORIAL
Valentin Favier, Jérémy Charriot, Louis Crampette, Arnaud Bourdin, Engi Ahmed
No abstract text is available yet for this article.
May 17, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37191185/an-international-delphi-study-on-the-burden-of-allergic-rhinoconjunctivitis-and-urticaria-and-the-role-of-bilastine-among-current-treatment-options
#8
JOURNAL ARTICLE
M K Church, G W Canonica, P Kuna, M Maurer, R Mösges, Z Novak, N G Papadopoulos, P Rodriguez Del Rio
BACKGROUND: allergic rhinoconjunctivitis and chronic urticaria are common histamine-driven diseases, exerting detrimental effects on cognitive functions, sleep, daily activities and quality of life. Non-sedating second-generation H1 -antihistamines are the first line treatment of choice. Aim of the study was to define the role of bilastine among second-generation H1 -antihistamines in the treatment of allergic rhinoconjunctivitis and urticaria in patients of different ages. METHODS: an international Delphi study was carried out to assess consensus among experts from 17 European and extra-European countries on three main topics: 1) Burden of disease; 2) Current treatment options; 3) Specific characteristics of bilastine among second generation antihistamines...
May 16, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37191153/secukinumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-in-pediatric-patients-aged-six-years-and-older
#9
REVIEW
Piotr K Krajewski, Jacek C Szepietowski
INTRODUCTION: Psoriasis (PSO) is a chronic, recurrent, inflammatory skin disorder that significantly influences patients' quality of life. The prevalence of PSO among children varies depending on the age and ranges from 0.12% at one year to 2% at 18 years. Due to systemic inflammation, PSO is associated with obesity, hypertension, inflammatory bowel disease, and cardiovascular incidences.Secukinumab is a fully human monoclonal antibody selectively targeting IL-17A. The drug has been approved for children aged 6-18 with moderate to severe plaque psoriasis...
May 16, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37190994/an-exercise-immune-fitness-test-to-unravel-mechanisms-of-post-acute-sequelae-of-covid-19
#10
EDITORIAL
Mario C Deng
The Post-Acute Sequelae of COVID-19 (PASC) Syndrome is a debilitating syndrome with onset three months post COVID-19 infection, marked by the presence of fatigue, headache, cognitive dysfunction, post-exertional malaise, orthostatic intolerance, and dyspnea that is clinically relevant and is at least as severe as fatigue in several other clinical conditions, including cancer. The onset, progression, and symptom profile of PASC patients have considerable overlap with Myalgic-Encephalopathy/Chronic Fatigue Syndrome (ME/CFS)...
May 16, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37190963/pharmacogenetics-of-childhood-uncontrolled-asthma
#11
REVIEW
Manaswitha Khare, Shraddha Piparia, Kelan G Tantisira
INTRODUCTION: Asthma is a heterogenous, multifactorial disease with multiple genetic and environmental risk factors playing a role in pathogenesis and therapeutic response. Understanding of pharmacogenetics can help with matching individualized treatments to specific genotypes of asthma to improve therapeutic outcomes especially in uncontrolled or severe asthma. AREAS COVERED: In this review, we outline novel information about biology, pathways and mechanisms related to interindividual variability in drug response (corticosteroids, bronchodilators, leukotriene modifiers and Biologics) for childhood asthma...
May 16, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37158055/clinical-pearls-and-promising-therapies-in-myositis
#12
REVIEW
Caoilfhionn M Connolly, Julie J Paik
INTRODUCTION: Idiopathic inflammatory myopathies (IIMs) represent a diverse group of systemic autoimmune disorders with variable clinical manifestations and disease course. Currently, the challenges of IIMs are multifold, including difficulties in timely diagnosis owing to clinical heterogeneity, limited insights into disease pathogenesis, as well as a restricted number of available therapies. However, advances utilizing myositis-specific autoantibodies (MSAs) have facilitated the definition of subgroups as well as prediction of clinical phenotypes, disease course, and response to treatment...
May 9, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37129440/peanut-allergy-risk-factors-immune-mechanisms-and-best-practices-for-oral-immunotherapy-success
#13
REVIEW
Jyothi Tirumalasetty, Suzanne Barshow, Laurie Kost, Lu Morales, Reyna Sharma, Carlos Lazarte, Kari C Nadeau
INTRODUCTION: Peanut oral immunotherapy (pOIT) is the only FDA-approved treatment for food allergy and its adoption amongst allergist immunologists and their patients is growing. pOIT is the subject of numerous clinical trials, however, the focus is often on treatment efficacy, safety, and tolerability, rather than identifying patients most likely to benefit from pOIT. Here, we review existing data on the clinical and immunological outcomes of pOIT that inform best practices for pOIT candidate selection...
May 2, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37122076/allergen-immunotherapy-progress-and-future-outlook
#14
REVIEW
Lara Šošić, Marta Paolucci, Stephan Flory, Fadi Jebbawi, Thomas M Kündig, Pål Johansen
INTRODUCTION: Allergy, the immunological hypersensitivity to innocuous environmental compounds, is a global health problem. The disease triggers, allergens, are mostly proteins contained in various natural sources such as plant pollen, animal dander, dust mites, foods, fungi and insect venoms. Allergies can manifest with a wide range of symptoms in various organs, and be anything from just tedious to life-threatening. A majority of all allergy patients are self-treated with symptom-relieving medicines, while allergen immunotherapy (AIT) is the only causative treatment option...
April 30, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37119005/a-prospective-single-arm-study-on-the-efficacy-and-safety-of-short-course-oral-corticosteroids-followed-by-topical-corticosteroids-in-patients-with-severe-chronic-rhinosinusitis-with-nasal-polyps
#15
JOURNAL ARTICLE
Shan Shao, Yue Wang, Nan Zhang, Yan Zhao, Xuelian Zhang, Yutong Sima, Ping Wang, Yuan Xu, Tie Wang, Shiping Bao, Yu Cao, Xiangdong Wang, Luo Zhang, Claus Bachert
BACKGROUND: Little evidence exists regarding an integrated multidimensional evaluation methodology to analyze the within-patient effects of medical treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). We aimed to use an integrated evaluation model to analyze the effects of short-course oral corticosteroid (OCS) followed by intranasal corticosteroid spray (INCS) therapy in patients with severe CRSwNP. METHODS: In all, 32 patients with severe CRSwNP received oral methylprednisolone for three weeks followed by intranasal budesonide spray for nine weeks in this prospective single-arm study...
April 29, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37114623/cellular-mechanisms-and-clinical-applications-for-phenocopies-of-inborn-errors-of-immunity-infectious-susceptibility-due-to-cytokine-autoantibodies
#16
JOURNAL ARTICLE
Rui Sun, Yating Wang, Hassan Abolhassani
INTRODUCTION: With a growing knowledge of Inborn error immunity (IEI), immunological profiling and genetic predisposition to IEI phenocopies have been developed in recent years. AREAS COVERED: Here we summarized the correlation between various pathogen invasions, autoantibody profiles, and corresponding clinical features in the context of patients with IEI phenocopies. It has been extensively evident that patients with anti-cytokine autoantibodies underly impaired anti-pathogen immune responses and lead to broad unregulated inflammation and tissue damage...
April 28, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37114372/biomarkers-guiding-biological-therapeutic-strategies-in-chronic-rhinosinusitis-with-nasal-polyps-an-emerging-challenge
#17
EDITORIAL
Bing Yan, Luo Zhang
No abstract text is available yet for this article.
April 28, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37114341/therapeutic-potential-of-jak-inhibitors-in-juvenile-idiopathic-arthritis-associated-uveitis
#18
JOURNAL ARTICLE
Ilaria Maccora, Preston Land, Virginia Miraldi Utz, Sheila T Angeles-Han
No abstract text is available yet for this article.
April 28, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37103889/budesonide-delayed-release-capsules-to-reduce-proteinuria-in-adults-with-primary-immunoglobulin-a-nephropathy
#19
JOURNAL ARTICLE
Jonathan Barratt, Richard A Lafayette, Brad H Rovin, Bengt Fellström
INTRODUCTION: Immunoglobulin A nephropathy (IgAN) is characterized by mesangial deposition of immune complexes containing galactose-deficient IgA1 (Gd-IgA1). This Gd-IgA1 is believed to originate from mucosally sited B cells, which are abundant in the Peyer's patches-rich distal ileum. Nefecon is a targeted-release form of budesonide developed to act in the distal ileum, thereby exerting a direct action on the mucosal tissue implicated in the pathogenesis of the disease. AREAS COVERED: This review discusses IgAN pathophysiology and provides an overview of the current therapeutic landscape, focusing on Nefecon, the first drug to receive accelerated US approval and conditional EU approval for the treatment of patients with IgAN at risk of rapid disease progression...
April 27, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37099717/machine-learning-method-for-the-cellular-phenotyping-of-nasal-polyps-from-multicentre-tissue-scans
#20
JOURNAL ARTICLE
Jing Ding, Changli Yue, Chengshuo Wang, Wei Liu, Libo Zhang, Bo Chen, Shen Shen, Yingshi Piao, Luo Zhang
BACKGROUND: This study aimed to establish a convenient and accurate chronic rhinosinusitis evaluation platform CRSAI 1.0 according to four phenotypes of nasal polyps. RESEARCH DESIGN AND METHODS: Tissue sections of a training (n = 54) and test cohort (n = 13) were sourced from the Tongren Hospital, and those for a validation cohort (n = 55) from external hospitals. Redundant tissues were automatically removed by the semantic segmentation algorithm of Unet++ with Efficientnet-B4 as backbone...
April 26, 2023: Expert Review of Clinical Immunology
journal
journal
41324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.